Antithrombotic Therapy for Venous Thromboembolic Disease

Chest - Tập 133 Số 6 - Trang 454S-545S - 2008
Clive Kearon1, Susan R. Kahn2, Giancarlo Agnelli3, Samuel Z. Goldhaber4, Gary E. Raskob5, Anthony J. Comerota6
1From McMaster University Clinic, Henderson General Hospital, Hamilton, ON, Canada
2Thrombosis Clinic and Centre for Clinical Epidemiology and Community Studies, Sir Mortimer B. Davis Jewish General Hospital, Montreal, QC, Canada
3University of Perugia, Perugia, Italy
4Brigham and Women's Hospital, Boston, MA
5College of Public Health, University of Oklahoma Health Science Center, Oklahoma City, OK
6Jobst Vascular Center, Toledo, OH

Tóm tắt

Từ khóa


Tài liệu tham khảo

Barritt, 1960, Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial, Lancet, 1, 1309, 10.1016/S0140-6736(60)92299-6

Alpert, 1976, Mortality in patients treated for pulmonary embolism, JAMA, 236, 1477, 10.1001/jama.1976.03270140029017

Kanis, 1974, Heparin in the treatment of pulmonary thromboembolism, Thrombos Diath Haemorrh, 32, 519, 10.1055/s-0038-1647720

Kernohan, 2007, Heparin therapy in thromboembolisc disease, Lancet, 1, 621

Brandjes, 1992, Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis, N Engl J Med, 327, 1485, 10.1056/NEJM199211193272103

Gallus, 1986, Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism, Lancet, 2, 1293, 10.1016/S0140-6736(86)91431-5

Hull, 1990, Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis, N Engl J Med, 322, 1260, 10.1056/NEJM199005033221802

Ansell, 2008, Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition), Chest, 160S, 10.1378/chest.08-0670

Crowther, 1999, A randomized trial comparing 5 mg and 10 mg warfarin loading doses, Arch Intern Med, 159, 46, 10.1001/archinte.159.1.46

Harrison, 1997, Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy, Ann Intern Med, 126, 133, 10.7326/0003-4819-126-2-199701150-00006

Kovacs, 2003, Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism: a randomized, double-blind, controlled trial, Ann Intern Med, 138, 714, 10.7326/0003-4819-138-9-200305060-00007

Garcia, 2005, Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population, Chest, 127, 2049, 10.1378/chest.127.6.2049

Levine, 2001, Hemorrhagic complications of anticoagulant treatment, Chest, 119, 108S, 10.1378/chest.119.1_suppl.108S

Basu, 1972, A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time, N Engl J Med, 287, 324, 10.1056/NEJM197208172870703

Cruickshank, 1991, A standard heparin nomogram for the management of heparin therapy, Arch Intern Med, 151, 333, 10.1001/archinte.1991.00400020085018

Raschke, 1996, The effectiveness of implementing the weight-based heparin nomogram as a practice guideline, Arch Intern Med, 156, 1645, 10.1001/archinte.1996.00440140067006

Raschke, 1993, The weight-based heparin dosing nomogram compared with a “standard care” nomogram, Ann Intern Med, 119, 874, 10.7326/0003-4819-119-9-199311010-00002

Anand, 1996, The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin, Arch Intern Med, 156, 1677, 10.1001/archinte.1996.00440140107010

Anand, 1999, Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin time results, Arch Intern Med, 159, 2029, 10.1001/archinte.159.17.2029

Hull, 1997, The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy, Arch Intern Med, 157, 2317, 10.1001/archinte.1997.00440410049005

Hull, 1997, Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis, Arch Intern Med, 157, 2562, 10.1001/archinte.1997.00440430038005

Levine, 1994, A randomized trial comparing the activated thromboplastin time with the heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin, Arch Intern Med, 154, 49, 10.1001/archinte.1994.00420010073009

Hommes, 1992, Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis, Ann Intern Med, 116, 279, 10.7326/0003-4819-116-4-279

Prandoni, 2004, Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism, Arch Intern Med, 164, 1077, 10.1001/archinte.164.10.1077

Kearon, 2006, Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism, JAMA, 296, 935, 10.1001/jama.296.8.935

Lim, 2006, Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency, Ann Intern Med, 144, 673, 10.7326/0003-4819-144-9-200605020-00011

Bates, 2004, Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy; evidence-based guidelines, Chest, 126, 627S, 10.1378/chest.126.3_suppl.627S

Breddin, 2001, Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis, N Engl J Med, 344, 626, 10.1056/NEJM200103013440902

Decousus, 1998, A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis, N Engl J Med, 338, 409, 10.1056/NEJM199802123380701

Duroux, 1991, A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis: a collaborative European multicentre study, Thromb Haemost, 65, 251, 10.1055/s-0038-1647660

Fiessinger, 1996, Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis, Thromb Haemost, 76, 195, 10.1055/s-0038-1650553

Harenberg, 2000, Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis: EASTERN Investigators, Thromb Haemost, 83, 652, 10.1055/s-0037-1613886

Hull, 1992, Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis, N Engl J Med, 326, 975, 10.1056/NEJM199204093261502

Kakkar, 2003, Low-molecular-weight heparin in the acute and long-term treatment of deep vein thrombosis, Thromb Haemost, 89, 674, 10.1055/s-0037-1613574

Kirchmaier, 1998, Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis: Certoparin Study Group, Int Angiol, 17, 135

Koopman, 1996, Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home, N Engl J Med, 334, 682, 10.1056/NEJM199603143341102

Levine, 1996, A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis, N Engl J Med, 334, 677, 10.1056/NEJM199603143341101

Lindmarker, 1994, Comparison of once-daily subcutaneous fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis, Thrombosis and Haemostasis, 72, 186, 10.1055/s-0038-1648836

Merli, 2001, Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease, Ann Intern Med, 134, 191, 10.7326/0003-4819-134-3-200102060-00009

Prandoni, 1992, Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis, Lancet, 339, 441, 10.1016/0140-6736(92)91054-C

Riess, 2003, Fixed-dose, body weight-independent subcutaneous low molecular weight heparin certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis, Thromb Haemost, 90, 252, 10.1160/TH02-09-0061

Simonneau, 1993, Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis, Arch Intern Med, 153, 1541, 10.1001/archinte.1993.00410130045005

Simonneau, 1997, A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism, N Engl J Med, 337, 663, 10.1056/NEJM199709043371002

1997, Low molecular weight heparin is an effective and safe treatment for deep-vein thrombosis and pulmonary embolism, N Engl J Med, 337, 657, 10.1056/NEJM199709043371001

Dolovich, 2000, A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency, Arch Intern Med, 160, 181, 10.1001/archinte.160.2.181

Gould, 1999, Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a meta-analysis of randomized, controlled trials, Ann Intern Med, 130, 800, 10.7326/0003-4819-130-10-199905180-00003

van Dongen, 2004, Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism, Cochrane Database Syst Rev, 10.1002/14651858.CD001100.pub2

Belcaro, 1999, Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis, Angiology, 50, 781, 10.1177/000331979905001001

Faivre, 1987, Subcutaneous administration of a low-molecular-weight-heparin (CY 222) compared with subcutaneous administration of standard heparin in patients with acute deep vein thrombosis [abstract], Thromb Haemost, 58, 1

Lopaciuk, 1992, Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial, Thromb Haemost, 68, 14, 10.1055/s-0038-1656309

Charbonnier, 1998, Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis, Thromb Haemost, 79, 897, 10.1055/s-0037-1615089

Holmstrom, 1992, Fragmin once or twice daily subcutaneously in the treatment of deep venous thrombosis of the leg, Thromb Res, 67, 49, 10.1016/0049-3848(92)90257-B

Partsch, 1996, Frequency of pulmonary embolism in patients who have iliofemoral deep vein thrombosis and are treated with once-or twice-daily low-molecular-weight heparin, J Vasc Surg, 24, 774, 10.1016/S0741-5214(96)70012-5

Siegbahn, 1989, Subcutaneous treatment of deep venous thrombosis with low molecular weight heparin: a dose finding study with LMWH-Novo, Thromb Res, 55, 767, 10.1016/0049-3848(89)90307-1

Couturaud, 2001, Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis, Thromb Haemost, 86, 980, 10.1055/s-0037-1616520

Boccalon, 2000, Clinical outcome and cost of hospital vs home treatment of proximal deep vein thrombosis with a low-molecular-weight heparin: the Vascular Midi-Pyrenees study, Arch Intern Med, 160, 1769, 10.1001/archinte.160.12.1769

Wells, 2005, A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism, Arch Intern Med, 165, 733, 10.1001/archinte.165.7.733

Faivre, 1988, A new treatment of deep venous thrombosis: low molecular weight heparin fractions; randomized study, Presse Med, 17, 197

Buller, 2004, Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial, Ann Intern Med, 140, 867, 10.7326/0003-4819-140-11-200406010-00007

Buller, 2003, Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism, N Engl J Med, 349, 1695, 10.1056/NEJMoa035451

Fiessinger, 2005, Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial, JAMA, 293, 681, 10.1001/jama.293.6.681

Buller, 2007, Idraparinux versus standard therapy for venous thromboembolic disease, N Engl J Med, 237, 1094

Bergan, 2006, Chronic venous disease, N Engl J Med, 355, 488, 10.1056/NEJMra055289

Cho, 1998, Effects of thrombolysis and venous thrombectomy on valvular competence, thrombogenicity, venous wall morphology, and function, J Vasc Surg, 28, 787, 10.1016/S0741-5214(98)70053-9

Johnson, 1995, Relationship between changes in the deep venous system and the development of the postthrombotic syndrome after an acute episode of lower limb deep vein thrombosis: a one- to six-year follow-up, J Vasc Surg, 21, 307, 10.1016/S0741-5214(95)70271-7

Killewich, 1989, Spontaneous lysis of deep venous thrombi: rate and outcome, J Vasc Surg, 9, 89, 10.1016/0741-5214(89)90223-1

Markel, 1992, Valvular reflux after deep vein thrombosis: incidence and time of occurrence, J Vasc Surg, 15, 377, 10.1016/0741-5214(92)90259-B

Meissner, 1993, Deep venous insufficiency: the relationship between lysis and subsequent reflux, J Vasc Surg, 18, 596, 10.1016/0741-5214(93)90069-X

Nicolaides, 1981, 488

Rhodes, 2000, Thrombolysis for experimental deep venous thrombosis maintains valvular competence and vasoreactivity, J Vasc Surg, 31, 1193, 10.1067/mva.2000.104421

Shull, 1979, Significance of popliteal reflux in relation to ambulatory venous pressure and ulceration, Arch Surg, 114, 1304, 10.1001/archsurg.1979.01370350106012

Elsharawy, 2002, Early results of thrombolysis vs anticoagulation in iliofemoral venous thrombosis: a randomised clinical trial, Eur J Vasc Endovasc Surg, 24, 209, 10.1053/ejvs.2002.1665

Plate, 1984, Thrombectomy with temporary arteriovenous fistula: the treatment of choice in acute iliofemoral venous thrombosis, J Vasc Surg, 1, 867, 10.1016/0741-5214(84)90019-3

Meissner MH, Mewissen M. Early outcome after catheterdirected thrombolysis for acute deep venous thrombosis: follow-up of a national multicenter registry. J Vasc Surg 2008 (in press)

Mewissen, 1999, Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry, Radiology, 211, 39, 10.1148/radiology.211.1.r99ap4739

Bjarnason, 1997, Iliofemoral deep venous thrombosis: safety and efficacy outcome during 5 years of catheter-directed thrombolytic therapy, J Vasc Interv Radiol, 8, 405, 10.1016/S1051-0443(97)70581-5

Comerota, 1994, A strategy of aggressive regional therapy for acute iliofemoral venous thrombosis with contemporary venous thrombectomy or catheter-directed thrombolysis, J Vasc Surg, 20, 244, 10.1016/0741-5214(94)90012-4

Comerota, 2000, Catheter-directed thrombolysis for the treatment of acute iliofemoral deep venous thrombosis, Phlebology, 15, 149

Comerota, 2000, Catheter-directed thrombolysis for iliofemoral deep venous thrombosis improves health-related quality of life, J Vasc Surg, 32, 130, 10.1067/mva.2000.105664

Juhan, 1997, Late results of iliofemoral venous thrombectomy, J Vasc Surg, 25, 417, 10.1016/S0741-5214(97)70249-0

Laiho, 2004, Preservation of venous valve function after catheter-directed and systemic thrombolysis for deep venous thrombosis, Eur J Vasc Endovasc Surg, 28, 391, 10.1016/j.ejvs.2004.06.007

Plate, 1990, Long-term results of venous thrombectomy combined with a temporary arterio-venous fistula, Eur J Vasc Surg, 4, 483, 10.1016/S0950-821X(05)80788-1

Plate, 1997, Venous thrombectomy for iliofemoral vein thrombosis: 10-year results of a prospective randomised study, Eur J Vasc Endovasc Surg, 14, 367, 10.1016/S1078-5884(97)80286-9

Akesson, 1990, Venous function assessed during a 5 year period after acute ilio-femoral venous thrombosis treated with anticoagulation, Eur J Vasc Surg, 4, 43, 10.1016/S0950-821X(05)80037-4

Delis, 2004, Venous claudication in iliofemoral thrombosis: long-term effects on venous hemodynamics, clinical status, and quality of life, Ann Surg, 239, 118, 10.1097/01.sla.0000103067.10695.74

O'Donnell, 1977, The socioeconomic effects of an iliofemoral venous thrombosis, J Surg Res, 22, 483, 10.1016/0022-4804(77)90030-0

Strandness, 1983, Long-term sequelae of acute venous thrombosis, JAMA, 250, 1289, 10.1001/jama.1983.03340100023022

Berridge, 1991, Randomized trial of intra-arterial recombinant tissue plasminogen activator, intravenous recombinant tissue plasminogen activator and intra-arterial streptokinase in peripheral arterial thrombolysis, Br J Surg, 78, 988, 10.1002/bjs.1800780831

AbuRahma, 2001, Iliofemoral deep vein thrombosis: conventional therapy versus lysis and percutaneous transluminal angioplasty and stenting, Ann Surg, 233, 752, 10.1097/00000658-200106000-00004

Castaneda, 2002, Catheter-directed thrombolysis in deep venous thrombosis with use of reteplase: immediate results and complications from a pilot study, J Vasc Interv Radiol, 13, 577, 10.1016/S1051-0443(07)61650-9

Grunwald, 2005, Comparison of urokinase, alteplase, and reteplase for catheter-directed thrombolysis of deep venous thrombosis, J Vasc Interv Radiol, 15, 347, 10.1097/01.RVI.0000121407.46920.15

Horne, 2000, Intraclot recombinant tissue plasminogen activator in the treatment of deep venous thrombosis of the lower and upper extremities, Am J Med, 108, 251, 10.1016/S0002-9343(99)00407-6

Jackson, 2005, Catheter-directed thrombolysis and/or thrombectomy with selective endovascular stenting as alternatives to systemic anticoagulation for treatment of acute deep vein thrombosis, Am J Surgery, 190, 864, 10.1016/j.amjsurg.2005.08.010

Kasirajan, 2001, Percutaneous AngioJet thrombectomy in the management of extensive deep venous thrombosis, J Vasc Interv Radiol, 12, 179, 10.1016/S1051-0443(07)61823-5

Kim, 2006, Adjunctive percutaneous mechanical thrombectomy for lower-extremity deep vein thrombosis: clinical and economic outcomes, J Vasc Interv Radiol, 17, 1099, 10.1097/01.RVI.0000228334.47073.C4

Lin, 2006, Catheter-direct thrombolysis versus pharmacomechanical thrombectomy for treatment of symptomatic lower extremity deep venous thrombosis, Am J Surg, 192, 782, 10.1016/j.amjsurg.2006.08.045

Ogawa, 2005, Intermittent pneumatic compression of the foot and calf improves the outcome of catheter-directed thrombolysis using low-dose urokinase in patients with acute proximal venous thrombosis of the leg, J Vasc Surg, 42, 940, 10.1016/j.jvs.2005.07.041

Semba, 1994, Iliofemoral deep venous thrombosis: aggressive therapy with catheter-directed thrombolysis, Radiology, 191, 487, 10.1148/radiology.191.2.8153327

Semba, 1996, Catheter-directed thrombolysis for iliofemoral venous thrombosis, SeminVasc Surg, 9, 26

Sillesen, 2005, Catheter-directed thrombolysis for treatment of ilio-femoral deep venous thrombosis is durable, preserves venous valve function and may prevent chronic venous insufficiency, Eur J Vasc Endovasc Surg, 30, 556, 10.1016/j.ejvs.2005.06.012

Vedantham, 2002, Lower extremity venous thrombolysis with adjunctive mechanical thrombectomy, J Vasc Interv Radiol, 13, 1001, 10.1016/S1051-0443(07)61864-8

Verhaeghe, 1997, Catheter-directed lysis of iliofemoral vein thrombosis with use of rt-PA, Eur Radiol, 7, 996, 10.1007/s003300050239

Arnesen, 1978, A prospective study of streptokinase and heparin in the treatment of deep vein thrombosis, Acta Med Scand, 203, 457, 10.1111/j.0954-6820.1978.tb14908.x

Arnesen, 1982, Streptokinase or heparin in the treatment of deep vein thrombosis: follow-up results of a prospective study, Acta Med Scand, 211, 65, 10.1111/j.0954-6820.1982.tb01904.x

Browse, 1968, Streptokinase and deep vein thrombosis, Br Med J, 3, 717, 10.1136/bmj.3.5620.717

Duckert, 1975, Treatment of deep vein thrombosis with streptokinase, Br Med J, 1, 479, 10.1136/bmj.1.5956.479

Elliot, 1979, A comparative randomized trial of heparin versus streptokinase in the treatment of acute proximal venous thrombosis: an interim report of a prospective trial, Br J Surg, 66, 838, 10.1002/bjs.1800661203

Goldhaber, 1990, Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis, Am J Med, 88, 235, 10.1016/0002-9343(90)90148-7

Kakkar, 1969, Treatment of deep vein thrombosis: a trial of heparin, streptokinase, and arvin, Br Med J, 1, 806, 10.1136/bmj.1.5647.806

Kiil, 1981, Urokinase or heparin in the management of patients with deep vein thrombosis?, Acta Chir Scand, 147, 529

Marder, 1977, Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy, J Lab Clin Med, 89, 1018

Porter, 1975, Comparison of heparin and streptokinase in the treatment of venous thrombosis, Am Surg, 41, 511

Robertson, 1968, Value of streptokinase and heparin in treatment of acute deep venous thrombosis: a coded investigation, Acta Chir Scand, 134, 203

Schulman, 1986, Long-term sequelae of calf vein thrombosis treated with heparin or low-dose streptokinase, Acta Med Scand, 219, 349, 10.1111/j.0954-6820.1986.tb03323.x

Schweizer, 1998, Comparative results of thrombolysis treatment with rt-PA and urokinase: a pilot study, VASA, 27, 167

Schweizer, 2000, Short- and long-term results after thrombolytic treatment of deep venous thrombosis, J Am Coll Cardiol, 36, 1336, 10.1016/S0735-1097(00)00863-9

Tsapogas, 1973, Controlled study of thrombolytic therapy in deep vein thrombosis, Surgery, 74, 973

Turpie, 1990, Tissue plasminogen activator (rt-PA) vs heparin in deep vein thrombosis: results of a randomized trial, Chest, 97, 172S

Verhaeghe, 1989, Multicenter pilot study of the efficacy and safety of systemic rt-PA administration in the treatment of deep vein thrombosis of the lower extremities and/or pelvis, Thromb Res, 55, 5, 10.1016/0049-3848(89)90451-9

Watz, 1979, Rapid thrombolysis and preservation of valvular venous function in high deep vein thrombosis: a comparative study between streptokinase and heparin therapy, Acta Med Scand, 205, 293, 10.1111/j.0954-6820.1979.tb06050.x

Watson, 2004, Thrombolysis for acute deep vein thrombosis, Cochrane Database Syst Rev, CD002783

Delomez, 2001, Mechanical thrombectomy in patients with deep venous thrombosis, Cardiovasc Intervent Radiol, 24, 42, 10.1007/s002700001658

Kinney, 2000, Pulmonary embolism from pulse-spray pharmacomechanical thrombolysis of clotted hemodialysis grafts: urokinase versus heparinized saline, J Vasc Interv Radiol, 11, 1143, 10.1016/S1051-0443(07)61355-4

Comerota, 2006, Technique of contemporary iliofemoral and infrainguinal venous thrombectomy, J Vasc Surg, 43, 185, 10.1016/j.jvs.2005.09.036

Karp, 1966, Recurrent thrombosis after iliofemoral venous thrombectomy, Surg Forum, 17, 147

Lansing, 1968, Five-year follow-up study of iliofemoral venous thrombectomy, Ann Surg, 168, 620, 10.1097/00000658-196810000-00009

Einarsson, 1986, and temporary AV-fistula in iliofemoral vein thrombosis: technical considerations and early results, Int Angiol, 5, 65

Einarsson, 1986, Follow-up evaluation of venous morphologic factors and function after thrombectomy and temporary arteriovenous fistula in thrombosis of iliofemoral vein, Surg Gynecol Obstet, 163, 111

Juhan, 1987, Patency after iliofemoral and iliocaval venous thrombectomy, Ann Vasc Surg, 1, 529, 10.1016/S0890-5096(06)61435-0

Kistner, 1979, in acute and chronic venous disease, Surgery, 85, 31

Meissner, 1996, strategy for management of deep venous thrombosis of the lower extremities, World J Surg, 20, 1149, 10.1007/s002689900175

Neglen, 1991, Iliofemoral venous thrombectomy followed by percutaneous closure of the temporary arteriovenous fistula, Surgery, 110, 493

Schwarzbach, 2005, Surgical thrombectomy followed by intraoperative endovascular reconstruction for symptomatic ilio-femoral venous thrombosis, Eur J Vasc Endovasc Surg, 29, 58, 10.1016/j.ejvs.2004.09.022

Torngren, 1988, and temporary arterio-venous fistula for ilio-femoral venous thrombosis, Int Angiol, 7, 14

2005, the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study, Circulation, 112, 416, 10.1161/CIRCULATIONAHA.104.512834

Streiff, 2000, Vena caval filters: a comprehensive review, Blood, 95, 3669, 10.1182/blood.V95.12.3669

White, 2000, A population-based study of the effectiveness of IVC filter use among patients with venous thromboembolism, Arch Intern Med, 160, 2033, 10.1001/archinte.160.13.2033

Aschwanden, 2001, Acute deep vein thrombosis: early mobilization does not increase the frequency of pulmonary embolism, Thromb Haemost, 85, 42, 10.1055/s-0037-1612901

Blattler, 2003, compression and ambulation is better than bed rest for the treatment of acute deep venous thrombosis, Int Angiol, 22, 393

Junger, 2006, Mobilization versus immobilization in the treatment of acute proximal deep venous thrombosis: a prospective, randomized, open, multicentre trial, Curr Med Res Opin, 22, 593, 10.1185/030079906X89838

Partsch, 2000, and walking versus bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin, J Vasc Surg, 32, 861, 10.1067/mva.2000.110352

Schellong, 1999, Bed rest in deep vein thrombosis and the incidence of scintigraphic pulmonary embolism, Thromb Haemost, 82, 127

Partsch, 2001, Therapy of deep vein thrombosis with low molecular weight heparin, leg compression and immediate ambulation, VASA, 30, 195, 10.1024/0301-1526.30.3.195

Partsch, 2004, mobilisation in acute vein thrombosis reduces post-thrombotic syndrome, Int Angiol, 23, 206

Trujillo-Santos, 2005, Bed rest or ambulation in the initial treatment of patients with acute deep vein thrombosis or pulmonary embolism: findings from the RIETE registry, Chest, 127, 1631, 10.1378/chest.127.5.1631

Lagerstedt, 1985, Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis, Lancet, 515, 10.1016/S0140-6736(85)90459-3

Hull, 1979, Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis, The N Engl J Med, 301, 855, 10.1056/NEJM197910183011602

Levine, 1995, Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis, Thromb Haemost, 74, 606, 10.1055/s-0038-1649783

1992, Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism, Lancet, 340, 873, 10.1016/0140-6736(92)93285-U

Schulman, 1997, The duration of oral anticoagulant therapy after a second episode of venous thromboembolism, N Engl J Med, 336, 393, 10.1056/NEJM199702063360601

Douketis, 1998, Risk of fatal pulmonary embolism in patients with treated venous thromboembolism, JAMA, 279, 458, 10.1001/jama.279.6.458

Linkins, 2003, impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis, Ann Intern Med, 139, 893, 10.7326/0003-4819-139-11-200312020-00007

Agnelli, 2003, Extended oral anticoagulant therapy after a first episode of pulmonary embolism, Ann Intern Med, 139, 19, 10.7326/0003-4819-139-1-200307010-00008

Agnelli, 2001, Three months versus one year of oral anticoagulant therapy for idiopathic deep vein thrombosis, N Engl J Med, 345, 165, 10.1056/NEJM200107193450302

Campbell, 2007, Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial, BMJ, 334, 674, 10.1136/bmj.39098.583356.55

Kearon, 1999, A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism, N Engl J Med, 340, 901, 10.1056/NEJM199903253401201

Kearon, 2004, Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor, J Thromb Haemost, 2, 743, 10.1046/j.1538-7836.2004.00698.x

Kearon, 2003, Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism, N Engl J Med, 349, 631, 10.1056/NEJMoa035422

Palareti, 2006, D-dimer testing to determine the duration of anticoagulation therapy, N Engl J Med, 355, 1780, 10.1056/NEJMoa054444

Pinede, 2001, Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis, Circulation, 103, 2453, 10.1161/01.CIR.103.20.2453

Ridker, 2003, Long-term, low-intensity warfarin therapy for prevention of recurrent venous thromboembolism, N Engl J Med, 348, 1425, 10.1056/NEJMoa035029

Schulman, 1995, A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism, N Engl J Med, 332, 1661, 10.1056/NEJM199506223322501

Heit, 2000, Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study, Arch Intern Med, 160, 761, 10.1001/archinte.160.6.761

Murin, 2002, of outcomes after hospitalization for deep vein thrombosis or pulmonary embolism, Thromb Haemost, 88, 407, 10.1055/s-0037-1613230

Palareti, 2002, Risk of venous thromboembolism recurrence: high negative predictive value of d-dimer performed after oral anticoagulation is stopped, Thromb Haemost, 87, 7, 10.1055/s-0037-1612936

Prandoni, 1996, The long-term clinical course of acute deep venous thrombosis, Ann Intern Med, 125, 1, 10.7326/0003-4819-125-1-199607010-00001

Pini, 1994, Low molecular weight heparin versus warfarin the prevention of recurrence after deep vein thrombosis, Thromb Haemost, 72, 191, 10.1055/s-0038-1648837

Baglin, 2003, Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study, Lancet, 362, 523, 10.1016/S0140-6736(03)14111-6

Christiansen, 2005, Thrombophilia, clinical factors, and recurrent venous thrombotic events, JAMA, 293, 2352, 10.1001/jama.293.19.2352

Hansson, 2000, venous thromboembolism after deep vein thrombosis: incidence and risk factors, Arch Intern Med, 160, 769, 10.1001/archinte.160.6.769

Schulman, 2003, Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran, N Engl J Med, 349, 1713, 10.1056/NEJMoa030104

Eichinger, 1999, The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene, Thromb Haemost, 81, 14, 10.1055/s-0037-1614409

Eichinger, 1997, The risk of recurrent venous thromboembolism in patients with and without Factor V Leiden, Thromb Haemost, 77, 624, 10.1055/s-0038-1656023

Ho, 2006, Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review, Arch Intern Med, 166, 729, 10.1001/archinte.166.7.729

Lindmarker, 1999, The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A Allele in the coagulation factor V gene and the G20210A Allele in the prothrombin gene, Thromb Haemost, 81, 684, 10.1055/s-0037-1614554

Miles, 2001, G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism, J Am Coll Cardiol, 37, 215, 10.1016/S0735-1097(00)01080-9

Palareti, 2003, Predictive value of d-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia, Circulation, 108, 313, 10.1161/01.CIR.0000079162.69615.0F

Ridker, 1995, Factor V Leiden and risks of recurrent idiopathic venous thromboembolism, Circulation, 92, 2800, 10.1161/01.CIR.92.10.2800

Schulman, 2006, Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months, J Thromb Haemost, 4, 734, 10.1111/j.1538-7836.2006.01795.x

Simioni, 2000, Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis, Blood, 96, 3329, 10.1182/blood.V96.10.3329

Schulman, 1985, The duration of oral anticoagulation after deep vein thrombosis, Acta Med Scand, 217, 547, 10.1111/j.0954-6820.1985.tb03261.x

Schulman, 2003, Unresolved issues in anticoagulant therapy, J Thromb Haemost, 1, 1464, 10.1046/j.1538-7836.2003.00269.x

Holmgren, 1985, One-month versus six-month therapy with oral anticoagulants after symptomatic deep vein thrombosis, Acta Med Scand, 218, 279, 10.1111/j.0954-6820.1985.tb06125.x

Ost, 2005, Duration of anticoagulation following venous thromboembolism: a meta-analysis, JAMA, 294, 706, 10.1001/jama.294.6.706

Kearon, 2003, Natural history of venous thromboembolism, Circulation, 107, I-22, 10.1161/01.CIR.0000078464.82671.78

Locadia, 2004, Treatment of venous thromboembolism with vitamin K antagonists: patients' health state valuations and treatment preferences, Thromb Haemost, 92, 1336, 10.1160/TH04-02-0075

Eichinger, 2003, D-dimer levels and risk of recurrent venous thromboembolism, JAMA, 290, 1071, 10.1001/jama.290.8.1071

Shrivastava, 2006, D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism, J Thromb Haemost, 4, 1208, 10.1111/j.1538-7836.2006.01935.x

Schulman, 1998, antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy, Am J Med, 104, 332, 10.1016/S0002-9343(98)00060-6

McRae, 2006, Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis, Lancet, 368, 371, 10.1016/S0140-6736(06)69110-1

White, 1998, of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California, Ann Intern Med, 128, 737, 10.7326/0003-4819-128-9-199805010-00006

Cosmi, 2005, D-dimer levels in combination with residual venous obstruction and the risk of recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis, Thromb Haemost, 94, 969, 10.1160/TH05-02-0095

Piovella, 2002, Normalization rates of compression ultrasonography in patients with a first episode of deep vein thrombosis of the lower limbs: association with recurrence and new thrombosis, Haematologica, 87, 515

Prandoni, 2002, Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism, Ann Intern Med, 137, 955, 10.7326/0003-4819-137-12-200212170-00008

Schulman, 2008, Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians evidence-based clinical practice guidelines, Chest, 133, 257S, 10.1378/chest.08-0674

Beyth, 2000, multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin: a randomized, controlled trial, Ann Intern Med, 133, 687, 10.7326/0003-4819-133-9-200011070-00010

Beyth, 1998, evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin, Am J Med, 105, 91, 10.1016/S0002-9343(98)00198-3

Dentali, 2007, Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials, Arch Intern Med, 167, 117, 10.1001/archinte.167.2.117

Gage, 2006, Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF), Am Heart J, 151, 713, 10.1016/j.ahj.2005.04.017

Kuijer, 1999, Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism, Arch Intern Med, 159, 457, 10.1001/archinte.159.5.457

Palareti, 1996, Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT), Lancet, 348, 423, 10.1016/S0140-6736(96)01109-9

Pengo, 2001, Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding: a Multicenter Inception Cohort Study, Thromb Haemost, 85, 418, 10.1055/s-0037-1615599

Crowther, 2003, A comparison of two intensities of warfarin for prevention of recurrent thrombosis in patients with antiphospholipid antibody syndrome, N Engl J Med, 349, 1133, 10.1056/NEJMoa035241

Finazzi, 2005, A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS), J Thromb Haemost, 3, 848, 10.1111/j.1538-7836.2005.01340.x

Hull, 1982, Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis, N Engl J Med, 307, 1676, 10.1056/NEJM198212303072704

Hull, 1982, Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis, N Engl J Med, 306, 189, 10.1056/NEJM198201283060401

Bynum, 1979, dose heparin therapy in the long-term management of venous thromboembolism, Am J Med, 67, 553, 10.1016/0002-9343(79)90224-9

Monreal, 1994, Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (fragmin) in patients with venous thromboembolism and contraindications to coumarin, Thromb Haemost, 71, 7, 10.1055/s-0038-1642376

Das, 1996, Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial, World J Surg, 20, 521, 10.1007/s002689900081

Hamann, 1998, Rezidivprophylaxe nach phlebothrombose-orale antikoagulation oder niedermolelulares heparin subkutan, Vasomed, 10, 133

Lee, 2003, Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer, N Engl J Med, 349, 146, 10.1056/NEJMoa025313

Gonzalez-Fajardo, 1999, Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis, J Vasc Surg, 30, 283, 10.1016/S0741-5214(99)70139-4

Meyer, 2002, Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study, Arch Intern Med, 162, 1729, 10.1001/archinte.162.15.1729

Veiga, 2000, Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial, Thromb Haemost, 84, 559, 10.1055/s-0037-1614067

Lopaciuk, 1999, Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis, Thromb Haemost, 81, 26, 10.1055/s-0037-1614412

Lopez-Beret, 2001, Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis, J Vasc Surg, 33, 77, 10.1067/mva.2001.109336

Hull, 2000, Long-term low molecular weight heparin treatment versus oral anticoagulant therapy for proximal deep vein thrombosis, Blood, 96, 449a

Hull, 2007, Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms, Am J Med, 120, 72, 10.1016/j.amjmed.2006.03.030

Iorio, 2003, -molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants, J Thromb Haemost, 1, 1906, 10.1046/j.1538-7836.2003.00364.x

van der Heijden JF, Hutten BA, Buller HR, et al. Vitamin K antagonists or low molecular weight heparin for the long term treatment of symptomatic venous thromboembolism (Cochrane Review). The Cochrane Library 2002; Issue 4 Oxford, UK: Update Software

Hull, 2006, Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer, Am J Med, 119, 1062, 10.1016/j.amjmed.2006.02.022

Weitz, 2008, New antithrombotic drugs: American College of Chest Physicians evidence-based clinical practice guidelines, Chest, 133, 234S, 10.1378/chest.08-0673

Buller, 2007, Extended prophylaxis of venous thromboembolism with idraparinux, N Engl J Med, 357, 1105, 10.1056/NEJMoa067703

Robinson, 1997, Ultrasonographic screening before hospital discharge for deep venous thrombosis after arthroplasty: the Post-Arthoplasty Screening Study; a randomized, controlled trial, Ann Intern Med, 127, 439, 10.7326/0003-4819-127-6-199709150-00004

Vaitkus, 2005, Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients, Thromb Haemost, 93, 76, 10.1160/TH04-05-0323

Kahn, 2002, The post-thrombotic syndrome: current knowledge, controversies, and directions for future research, Blood Rev, 16, 155, 10.1016/S0268-960X(02)00008-5

Brandjes, 1997, Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis, Lancet, 349, 759, 10.1016/S0140-6736(96)12215-7

Ginsberg, 2001, Prevention and treatment of postphlebitic syndrome: results of a 3-part study, Arch Intern Med, 161, 2105, 10.1001/archinte.161.17.2105

Prandoni, 2004, Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial, Ann Intern Med, 141, 249, 10.7326/0003-4819-141-4-200408170-00004

Kolbach, 2004, Non-pharmaceutical measures for prevention of post-thrombotic syndrome, Cochrane Database Syst Rev, CD004174

Kahn, 2007, Effectiveness of compression stockings to prevent the post-thrombotic syndrome (the SOX Trial and Bio-SOX biomarker substudy): a randomized controlled trial, BMC Cardiovasc Dis, 7, 21, 10.1186/1471-2261-7-21

Ginsberg, 1999, Intermittent compression units for severe post-phlebitic syndrome: a randomized crossover study, Can Med Assoc J, 160, 1303

Smith, 1990, Sequential gradient pneumatic compression enhances venous ulcer healing: a randomized trial, Surgery, 108, 871

Kumar, 2002, Intermittent pneumatic compression as an adjuvant therapy in venous ulcer disease, J Tissue Viability, 12, 42, 10.1016/S0965-206X(02)80013-4

Kolari, 1988, Transcutaneous oxygen tension in patients with post-thrombotic leg ulcers: treatment with intermittent pneumatic compression, Cardiovasc Res, 22, 138, 10.1093/cvr/22.2.138

Barwell, 2004, Comparison of surgery and compression with compression alone in chronic venous ulceration (ESCHAR study): randomised controlled trial, Lancet, 363, 1854, 10.1016/S0140-6736(04)16353-8

Gohel, 2007, Long term results of compression therapy alone versus compression plus surgery in chronic venous ulceration (ESCHAR): randomised controlled trial, BMJ, 335, 83, 10.1136/bmj.39216.542442.BE

Hammarlund, 1994, Hyperbaric oxygen reduced size of chronic leg ulcers: a randomized double-blind study, Plast Reconstr Surg, 93, 829, 10.1097/00006534-199404000-00026

Martin, 1993, PHLECO: a multicenter study of the fate of 1647 hospital patients treated conservatively without fibrinolysis and surgery, Clin Investig, 71, 471, 10.1007/BF00180062

Arenas, 1988, Postthrombotic leg ulcers: safety and efficacy of treatment with pentoxifylline (double-blind study in 30 patients), Dermatologia Revista Mexicana, 32, 34

Barbarino, 1992, Pentoxifylline in the treatment of venous leg ulcers, Curr Med Res Opin, 12, 547, 10.1185/03007999209111520

Colgan, 1989, The efficacy of Trental in the tratment of venous ulceration, Phlebologie, 1154

Dale, 1999, Randomised, double blind placebo controlled trial of pentoxifylline in the treatment of venous leg ulcers, BMJ, 319, 875, 10.1136/bmj.319.7214.875

Falanga, 1999, Systemic treatment of venous leg ulcers with high doses of pentoxifylline: efficacy in a randomized, placebo-controlled trial, Wound Repair Regen, 7, 208, 10.1046/j.1524-475X.1999.00208.x

Herdy, 1997, Efficacy of pentoxifylline in the healing of venous leg ulcers: a clinical comparative study, Arquivos Brasileiros de Medicina, 71, 157

Schurman, 1986, The efficacy of pentoxifylline added to topical and compression therapy in patients with varicose and postthrombotic leg ulcers, Therapiewoche, 36, 2343

Weitgasser, 1983, The use of pentoxifylline (Trental 400) in the treatment of leg ulcers: results of a double-blind trial, Pharmatherapeutica, 2, 143

Nikolovska, 2002, Pentoxifylline: efficient in the treatment of venous ulcers in the absence of compression?, Acta Dermatovenerol Croat, 10, 9

Lyseng-Williamson, 2003, Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids, Drugs, 63, 71, 10.2165/00003495-200363010-00005

Shoab, 1999, Endothelial activation response to oral micronised flavonoid therapy in patients with chronic venous disease: a prospective study, Eur J Vasc Endovasc Surg, 17, 313, 10.1053/ejvs.1998.0751

Garner, 2002, Comparison of the absorption of micronized (Daflon 500 mg) and nonmicronized 14C-diosmin tablets after oral administration to healthy volunteers by accelerator mass spectrometry and liquid scintillation counting, J Pharm Sci, 91, 32, 10.1002/jps.1168

Coleridge-Smith, 2005, Venous leg ulcer: a meta-analysis of adjunctive therapy with micronized purified flavonoid fraction, Eur J Vasc Endovasc Surg, 30, 198, 10.1016/j.ejvs.2005.04.017

Coccheri, 2002, Randomised, double blind, multicentre, placebo controlled study of sulodexide in the treatment of venous leg ulcers, Thromb Haemost, 87, 947, 10.1055/s-0037-1613116

Campbell, 1998, Duration of hospital stay in patients with pulmonary venous thromboembolism: a randomized comparison of unfractionated heparinversus low molecular weight heparin [abstract], Thorax, 53, 254

Kuijer, 1995, Randomized comparison of LMWH versus standard heparin in the initial treatment of pulmonary embolism [abstract], Thromb Haemost, 73, 974

Meyer, 1995, Subcutaneous low-molecular-weight heparin fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomized pilot study, Thromb Haemost, 74, 1432, 10.1055/s-0038-1649960

Perez de Llano, 2003, Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism, Arch Bronconeumol, 39, 341, 10.1016/S0300-2896(03)75401-5

Thery, 1992, Randomized trial of subcutaneous low-molecular-weight heparin CY 216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism, Circulation, 85, 1380, 10.1161/01.CIR.85.4.1380

Quinlan, 2004, Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials, Ann Intern Med, 140, 175, 10.7326/0003-4819-140-3-200402030-00008

Beer, 2003, Outpatient treatment of pulmonary embolism is feasible and safe in a substantial proportion of patients, J Thromb Haemost, 1, 186, 10.1046/j.1538-7836.2003.00005.x

Kovacs, 2000, Outpatient treatment of pulmonary embolism with dalteparin, Thromb Haemost, 83, 209, 10.1055/s-0037-1613787

Wells, 1998, Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin, Arch Intern Med, 158, 1809, 10.1001/archinte.158.16.1809

Wicki, 2000, Predicting adverse outcome in patients with acute pulmonary embolism: a risk score, Thromb Haemost, 84, 548, 10.1055/s-0037-1614065

Aujesky, 2005, Derivation and validation of a prognostic model for pulmonary embolism, Am J Respir Crit Care Med, 172, 1041, 10.1164/rccm.200506-862OC

Jimenez, 2007, Prognostic models for selecting patients with acute pulmonary embolism for initial outpatient therapy, Chest, 132, 24, 10.1378/chest.06-2921

Agnelli, 2002, Thrombolysis vs heparin in the treatment of pulmonary embolism: a clinical outcome-based meta-analysis, Arch Intern Med, 162, 2537, 10.1001/archinte.162.22.2537

Dong, 2006, Thrombolytic treatment for pulmonary embolism, Cochrane Database Syst Rev, 2, cD004437

Wan, 2004, Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials, Circulation, 110, 744, 10.1161/01.CIR.0000137826.09715.9C

1973, a national co-operative study, Circulation, 47, 1

Dalla-Volta, 1992, PAIMS 2-alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism: plasminogen Activator Italian Multicenter Study 2, J Am Coll Cardiol, 20, 520, 10.1016/0735-1097(92)90002-5

Dotter, 1979, Streptokinase and heparin in the treatment of pulmonary embolism: a randomized comparison, Vasc Surg, 13, 42, 10.1177/153857447901300107

1990, Tissue plasminogen activator for the treatment of acute pulmonary embolism, Chest, 97, 528, 10.1378/chest.97.3.528

Jerjes-Sanchez, 1995, Streprokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial, J Thromb Thrombol, 2, 227, 10.1007/BF01062714

Lopaciuk S, Meissner AJ, Ciesielski L, et al. Subcutaneous sodium heparin versus intravenous sodium heparin in the treatment of deep vein thrombosis: proceedings of the 6th International Meeting of the Danubian League Against Thrombosis and Haemorrhagic Disorders. Vienna, Austria: 1989; 389-393

Ly, 1978, A controlled clinical trial of streptokinse and heparin in the treatment of major pulmonary embolism, Acta Med Scand, 203, 465, 10.1111/j.0954-6820.1978.tb14909.x

Marini, 1988, Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism: a randomized clinical trial, Respiration, 54, 162, 10.1159/000195517

Tibbutt, 1974, Comparison by controlled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonary embolism, BMJ, 1, 343, 10.1136/bmj.1.5904.343

1970, Urokinase pulmonary embolism trial: phase I results, JAMA, 214, 2163, 10.1001/jama.1970.03180120035007

Konstantinides, 2002, Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism, N Engl J Med, 347, 1143, 10.1056/NEJMoa021274

Kucher, 2006, Massive pulmonary embolism, Circulation, 113, 577, 10.1161/CIRCULATIONAHA.105.592592

Goldhaber, 1999, Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER), Lancet, 353, 1386, 10.1016/S0140-6736(98)07534-5

Douketis, 2005, The incidence and prognostic significance of elevated cardiac troponins in patients with submassive pulmonary embolism, J Thromb Haemost, 3, 508, 10.1111/j.1538-7836.2005.01189.x

Giannitsis, 2005, Risk stratification in pulmonary embolism based on biomarkers and echocardiography, Circulation, 112, 1520, 10.1161/CIRCULATIONAHA.105.566182

Konstantinides, 2002, Importance of cardiac troponins I and T in risk stratification of patients with acute pulmonary embolism, Circulation, 106, 1263, 10.1161/01.CIR.0000028422.51668.A2

Scridon, 2005, Prognostic significance of troponin elevation and right ventricular enlargement in acute pulmonary embolism, Am J Cardiol, 96, 303, 10.1016/j.amjcard.2005.03.062

Becattini, 2007, Prognostic value of troponins in acute pulmonary embolism: a meta-analysis, Circulation, 116, 427, 10.1161/CIRCULATIONAHA.106.680421

Goldhaber, 2002, Echocardiography in the management of pulmonary embolism, Ann Intern Med, 136, 691, 10.7326/0003-4819-136-9-200205070-00012

Schoepf, 2004, Right ventricular enlargement on chest computed tomography: a predictor of early death in acute pulmonary embolism, Circulation, 110, 3276, 10.1161/01.CIR.0000147612.59751.4C

Ten Wolde, 2004, Prognostic value of echocardiographically assessed right ventricular dysfunction in patients with pulmonary embolism, Arch Intern Med, 164, 1685, 10.1001/archinte.164.15.1685

Fiumara, 2006, Predictors of major hemorrhage following fibrinolysis for acute pulmonary embolism, Am J Cardiol, 97, 127, 10.1016/j.amjcard.2005.07.117

Kanter, 1997, Thrombolytic therapy for pulmonary embolism: frequency of intracranial hemorrhage and associated risk factors, Chest, 111, 1241, 10.1378/chest.111.5.1241

1974, phase 2 result, JAMA, 229, 1606

Goldhaber, 1994, Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis: an international multicenter randomized trial; The Bolus Alteplase Pulmonary Embolism Group, Chest, 106, 718, 10.1378/chest.106.3.718

Goldhaber, 1988, A randomized controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism, Lancet, 2, 293, 10.1016/S0140-6736(88)92354-9

Goldhaber, 1992, Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial, J Am Coll Cardiol, 20, 24, 10.1016/0735-1097(92)90132-7

Meneveau, 1998, Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one-year follow-up, J Am Coll Cardiol, 31, 1057, 10.1016/S0735-1097(98)00068-0

Meneveau, 1997, Streptokinase vs alteplase in massive pulmonary embolism: a randomized trial assessing right heart haemodynamics and pulmonary vascular obstruction, Eur Heart J, 18, 1141, 10.1093/oxfordjournals.eurheartj.a015410

Meyer, 1992, Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial, J Am Coll Cardiol, 19, 239, 10.1016/0735-1097(92)90472-Y

Sors, 1994, Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism: a randomized controlled multicenter trial, Chest, 106, 712, 10.1378/chest.106.3.712

Verstraete, 1988, Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism, Circulation, 77, 353, 10.1161/01.CIR.77.2.353

Levine, 1990, A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism, Chest, 98, 1473, 10.1378/chest.98.6.1473

Gregorio, 2001, Mechanical fragmentation and intrapulmonary fibrinolysis in the treatment of massive pulmonary embolism hemodynamic repercussions, Arch Bronconeumol, 37, 58

Fava, 1997, Mechanical fragmentation and pharmacologic thrombolysis in massive pulmonary embolism, J Vasc Interv Radiol, 8, 261, 10.1016/S1051-0443(97)70552-9

Schmitz-Rode, 2000, Massive pulmonary embolism: percutaneous emergency treatment by pigtail rotation catheter, J Am Coll Cardiol, 36, 375, 10.1016/S0735-1097(00)00734-8

Schmitz-Rode, 1998, Fragmentation of massive pulmonary embolism using a pigtail rotation catheter, Chest, 114, 1427, 10.1378/chest.114.5.1427

Leacche, 2005, Modern surgical treatment of massive pulmonary embolism: results in 47 consecutive patients after rapid diagnosis and aggressive surgical approach, J Thorac Cardiovasc Surg, 129, 1018, 10.1016/j.jtcvs.2004.10.023

Meneveau, 2006, Management of unsuccessful thrombolysis in acute massive pulmonary embolism, Chest, 129, 1043, 10.1378/chest.129.4.1043

Sukhija, 2005, Association of right ventricular dysfunction with in-hospital mortality in patients with acute pulmonary embolism and reduction in mortality in patients with right ventricular dysfunction by pulmonary embolectomy, Am J Cardiol, 95, 695, 10.1016/j.amjcard.2004.10.055

Beckman, 2003, Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism, Thromb Haemost, 89, 953, 10.1055/s-0037-1613395

Kucher, 2005, Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism, Vasc Med, 10, 251, 10.1191/1358863x05vm634oa

Gosselin, 1998, Unsuspected pulmonary embolism: prospective detection on routine helical CT scans, Radiology, 208, 209, 10.1148/radiology.208.1.9646815

O'Connell, 2006, Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance, J Clin Oncol, 24, 4928, 10.1200/JCO.2006.06.5870

Sebastian, 2006, Clinically unsuspected pulmonary embolism-an important secondary finding in oncology CT, Clin Radiol, 61, 81, 10.1016/j.crad.2005.09.002

Storto, 2005, Incidental detection of pulmonary emboli on routine MDCT of the chest, AJR Am J Roentgenol, 184, 264, 10.2214/ajr.184.1.01840264

Becattini, 2006, Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism, Chest, 130, 172, 10.1378/chest.130.1.172

Pengo, 2004, Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism, N Engl J Med, 350, 2257, 10.1056/NEJMoa032274

Ribeiro, 1999, Pulmonary embolism: one year follow-up with echocardiography doppler and five-year survival analysis, Circulation, 99, 1325, 10.1161/01.CIR.99.10.1325

Jamieson, 2003, Pulmonary endarterectomy: experience and lessons learned in 1,500 cases, Ann Thorac Surg, 76, 1457, 10.1016/S0003-4975(03)00828-2

Fedullo, 2001, Chronic thromboembolic pulmonary hypertension, N Engl J Med, 345, 1465, 10.1056/NEJMra010902

Feinstein, 2001, Balloon pulmonary angioplasty for treatment of chronic thromboembolic pulmonary hypertension, Circulation, 103, 10, 10.1161/01.CIR.103.1.10

Galie, 2006, Pulmonary microvascular disease in chronic thromboembolic pulmonary hypertension, Proc Am Thorac Soc, 3, 571, 10.1513/pats.200605-113LR

Hoeper, 2006, Chronic thromboembolic pulmonary hypertension, Circulation, 113, 2011, 10.1161/CIRCULATIONAHA.105.602565

Bresser, 2006, Medical therapies for chronic thromboembolic pulmonary hypertension: an evolving treatment paradigm, Proc Am Thorac Soc, 3, 594, 10.1513/pats.200605-115LR

Skoro-Sajer, 2007, Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension, J Thromb Haemost, 5, 483, 10.1111/j.1538-7836.2007.02394.x

Hughes, 2006, The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study, Eur Respir J, 28, 138, 10.1183/09031936.06.00135905

Tagalakis, 2002, The epidemiology of peripheral vein infusion thrombophlebitis: a critical review, Am J Med, 113, 146, 10.1016/S0002-9343(02)01163-4

Becherucci, 2000, Effect of topical and oral diclofenac on superficial thrombophlebitis caused by intravenous infusion, Med Clin (Barc), 114, 371, 10.1016/S0025-7753(00)71300-5

Vilardell, 1999, Topical heparin for the treatment of acute superficial phlebitis secondary to indwelling intravenous catheter: a double-blind, randomized, placebo-controlled trial, Eur J Clin Pharmacol, 54, 917, 10.1007/s002280050575

Bergqvist, 1990, Treatment of superficial thrombophlebitis: a comparative trial between placebo, Hirudoid cream and piroxicam gel, Ann Chir Gynaecol, 79, 92

De Sanctis, 2001, Treatment of superficial vein thrombophlebitis of the arm with Essaven gel: a placebo-controlled, randomized study, Angiology, 52, S63, 10.1177/0003319701052003S12

Decousus, 2003, Superficial vein thrombosis: risk factors, diagnosis, and treatment, Curr Opin Pulm Med, 9, 393, 10.1097/00063198-200309000-00009

Wichers, 2005, Treatment of superficial vein thrombosis to prevent deep vein thrombosis and pulmonary embolism: a systematic review, Haematologica, 90, 672

Quenet, 2003, Factors predictive of venous thrombotic complications in patients with isolated superficial vein thrombosis, J Vasc Surg, 38, 944, 10.1016/S0741-5214(03)00607-4

Di Nisio, 2007, Treatment for superficial thrombophlebitis of the leg, Cochrane Database Syst Rev, CD004982

2003, A pilot randomized double-blind comparison of a low-molecular-weight heparin, a nonsteroidal anti-inflammatory agent, and placebo in the treatment of superficial vein thrombosis, Arch Intern Med, 163, 1657, 10.1001/archinte.163.14.1657

Titon, 1994, Therapeutic management of superficial venous thrombosis with calcium nadroparin: dosage testing and comparison with a non-steroidal anti-inflammatory agent, Ann Cardiol Angeiol (Paris), 43, 160

Prandoni, 2005, High vs. low doses of low-molecular-weight heparin for the treatment of superficial vein thrombosis of the legs: a double-blind, randomized trial, J Thromb Haemost, 3, 1152, 10.1111/j.1538-7836.2005.01391.x

Marchiori, 2002, High versus low doses of unfractionated heparin for the treatment of superficial thrombophlebitis of the leg: a prospective, controlled, randomized study, Haematologica, 87, 523

Belcaro, 1999, Superficial thrombophlebitis of the legs: a randomized, controlled, follow-up study, Angiology, 50, 523, 10.1177/000331979905000701

Gorski, 2005, Liposomal heparin spray: a new formula in adjunctive treatment of superficial venous thrombosis, Angiology, 56, 9, 10.1177/000331970505600102

Andreozzi, 1996, Tolerability and clinical efficacy of desmin in the treatment of superficial thrombovaricophlebitis, Angiology, 47, 887, 10.1177/000331979604700907

Lozano, 2003, Low-molecular-weight heparin versus saphenofemoral disconnection for the treatment of above-knee greater saphenous thrombophlebitis: a prospective study, Vasc Endovascular Surg, 37, 415, 10.1177/153857440303700605

Sullivan, 2001, Ligation versus anticoagulation: treatment of above-knee superficial thrombophlebitis not involving the deep venous system, J Am Coll Surg, 193, 556, 10.1016/S1072-7515(01)01043-2

Becker, 1991, Axillary and subclavian venous thrombosis: prognosis and treatment, Arch Intern Med, 151, 1934, 10.1001/archinte.1991.00400100022004

Joffe, 2004, Upper-extremity deep vein thrombosis: a prospective registry of 592 patients, Circulation, 110, 1605, 10.1161/01.CIR.0000142289.94369.D7

Prandoni, 1997, Upper-extremity deep vein thrombosis: risk factors, diagnosis, and complications, Arch Intern Med, 157, 57, 10.1001/archinte.1997.00440220061008

Prandoni, 2004, The long term clinical course of acute deep vein thrombosis of the arm: prospective cohort study, BMJ, 329, 484, 10.1136/bmj.38167.684444.3A

Elman, 2006, The post-thrombotic syndrome after upper extremity deep venous thrombosis: a systematic review, Thromb Res, 117, 609, 10.1016/j.thromres.2005.05.029

Savage, 1999, Outpatient use of low molecular weight heparin (dalteparin) for the treatment of deep vein thrombosis of the upper extremity, Thromb Haemost, 82, 1008, 10.1055/s-0037-1614319

Karabay, 2004, Upper extremity deep vein thrombosis: clinical and treatment characteristics, J Int Med Res, 32, 429, 10.1177/147323000403200413

Kovacs, 2007, A pilot study of central venous catheter survival in cancer patients using low molecular weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study), J Thromb Haemost, 5, 1650, 10.1111/j.1538-7836.2007.02613.x

AbuRahma, 1996, Treatment alternatives for axillary-subclavian vein thrombosis: long-term follow-up, Cardiovasc Surg, 4, 783, 10.1016/S0967-2109(96)00025-7

Lee, 2006, Long-term thrombotic recurrence after nonoperative management of Paget-Schroetter syndrome, J Vasc Surg, 43, 1236, 10.1016/j.jvs.2006.02.005

Lokanathan, 2001, Outcome after thrombolysis and selective thoracic outlet decompression for primary axillary vein thrombosis, J Vasc Surg, 33, 783, 10.1067/mva.2001.112708

Pegis, 1997, thrombolysis in the treatment of venous thrombosis of effort in the arm, J Mal Vasc, 22, 187

Petrakis, 2000, Two different therapeutic modalities in the treatment of the upper extremity deep vein thrombosis: preliminary investigation with 20 case reports, Int J Angiol, 9, 46, 10.1007/BF01616331

Sabeti, 2002, Treatment of subclavian-axillary vein thrombosis: long-term outcome of anticoagulation versus systemic thrombolysis, Thromb Res, 108, 279, 10.1016/S0049-3848(03)00093-8

Schindler, 1999, Regional thrombolysis with urokinase for central venous catheter-related thrombosis in patients undergoing high-dose chemotherapy with autologous blood stem cell rescue, Clin Appl Thromb Haemost, 5, 25, 10.1177/107602969900500106

Caparrelli, 2005, A unified approach to axillosubclavian venous thrombosis in a single hospital admission, Semin Vasc Surg, 18, 153, 10.1053/j.semvascsurg.2005.05.007

Thomas, 2005, An integrative review of outcomes in patients with acute primary upper extremity deep venous thrombosis following no treatment or treatment with anticoagulation, thrombolysis, or surgical algorithms, Vasc Endovascular Surg, 39, 163, 10.1177/153857440503900206

Machleder, 1993, Evaluation of a new treatment strategy for Paget-Schroetter syndrome: spontaneous thrombosis of the axillary-subclavian vein, J Vasc Surg, 17, 305, 10.1016/0741-5214(93)90416-J

Schneider, 2004, Combination treatment of venous thoracic outlet syndrome: open surgical decompression and intraoperative angioplasty, J Vasc Surg, 40, 599, 10.1016/j.jvs.2004.07.028

Spence, 1999, Acute upper extremity deep venous thrombosis: safety and effectiveness of superior vena caval filters, Radiology, 210, 53, 10.1148/radiology.210.1.r99ja1353

Ascher, 2000, Lessons learned from a 6-year clinical experience with superior vena cava Greenfield filters, J Vasc Surg, 32, 881, 10.1067/mva.2000.110883

Feugier, 2001, Long-term results of venous revascularization for Paget-Schroetter syndrome in athletes, Ann Vasc Surg, 15, 212, 10.1007/s100160010043

Lee, 1998, Early operative intervention after thrombolytic therapy for primary subclavian vein thrombosis: an effective treatment approach, J Vasc Surg, 27, 1101, 10.1016/S0741-5214(98)70012-6

Malcynski, 1993, Long-term results of treatment for axillary subclavian vein thrombosis, Can J Surg, 36, 365

Meier, 1996, Initial experience with venous stents in exertional axillary-subclavian vein thrombosis, J Vasc Surg, 24, 974, 10.1016/S0741-5214(96)70043-5

Sanders, 1995, Surgical management of subclavian vein obstruction, including six cases of subclavian vein bypass, Surgery, 118, 856, 10.1016/S0039-6060(05)80276-4

Sheeran, 1997, Local thrombolytic therapy as part of a multidisciplinary approach to acute axillosubclavian vein thrombosis (Paget-Schroetter syndrome), J Vasc Interv Radiol, 8, 253, 10.1016/S1051-0443(97)70551-7

Urschel, 2003, Paget-Schroetter syndrome therapy: failure of intravenous stents, Ann Thorac Surg, 75, 1693, 10.1016/S0003-4975(03)00116-4

Yilmaz, 2000, Long-term results of local thrombolysis followed by first rib resection: an encouraging clinical experience in treatment of subclavian vein thrombosis, Vasc Surg, 34, 17, 10.1177/153857440003400105

Marie, 1998, Deep venous thrombosis of the upper limbs: apropos of 49 cases [in French], Rev Med Interne, 19, 399, 10.1016/S0248-8663(98)80864-3

Baarslag, 2004, Diagnosis and management of deep vein thrombosis of the upper extremity: a review, Eur Radiol, 14, 1263, 10.1007/s00330-004-2252-1

Buller, 2004, Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy, Chest, 126, 401S, 10.1378/chest.126.3_suppl.401S

Elliott, 1997, Upper-extremity deep vein thrombosis, Lancet, 349, 1188, 10.1016/S0140-6736(05)62408-7

Joffe, 2002, Upper-extremity deep vein thrombosis, Circulation, 106, 1874, 10.1161/01.CIR.0000031705.57473.1C

Martinelli, 2004, Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities, Circulation, 110, 566, 10.1161/01.CIR.0000137123.55051.9B

Burihan, 1993, Upper-extremity deep venous thrombosis: analysis of 52 cases, Cardiovasc Surg, 1, 19, 10.1177/096721099300100106

Hingorani, 1997, Upper extremity deep venous thrombosis and its impact on morbidity and mortality rates in a hospital-based population, J Vasc Surg, 26, 853, 10.1016/S0741-5214(97)70100-9

Hingorani, 2001, Combined upper and lower extremity deep venous thrombosis, Cardiovasc Surg, 9, 472, 10.1016/S0967-2109(01)00039-4

Lindblad, 1988, Deep vein thrombosis of the axillary-subclavian veins: epidemiologic data, effects of different types of treatment and late sequelae, Eur J Vasc Surg, 2, 161, 10.1016/S0950-821X(88)80069-0

Marinella, 2000, Spectrum of upper-extremity deep venous thrombosis in a community teaching hospital, Heart Lung, 29, 113, 10.1067/mhl.2000.105758

Kahn, 2005, Post-thrombotic syndrome, functional disability and quality of life after upper extremity deep venous thrombosis in adults, Thromb Haemost, 93, 499, 10.1160/TH04-10-0640

Apollonio, 1992, Conservative treatment of venous leg ulcers (pentoxifylline vs defibrotide) [in Italian], Giornale Italiano di Angiologia, 12, 151

Belcaro, 2002, Treatment of venous ulcers with pentoxifylline: a 6-month randomized, double-blind, placebo controlled trial, Angiology, 53, S45

De Sanctis, 2002, Treatment of venous ulcers with pentoxifylline: a 12-month, double-blind, placebo controlled trial. Microcirculation and healing, Angiology, 53, S49

Guilhou, 1997, Benefit of a 2-month treatment with a micronized, purified flavonoidic fraction on venous ulcer healing: a randomized, double-blind, controlled versus placebo trial, Int J Microcirc Clin Exp, 17, 21, 10.1159/000179263

Glinski, 2001, Effectiveness of a micronized purified flavonoid fraction (MPFF) in the healing process of lower limb ulcers: an open multicentre study, controlled and randomized [in Italian], Minerva Cardioangiol, 49, 107

Roztocil, 2003, Efficacy of a 6-month treatment with Daflon 500 mg in patients with venous leg ulcers associated with chronic venous insufficiency, Int Angiol, 22, 24

Goldhaber, 1993, Aleptase versus heparin in acute pulmonary embolism: randomized trial assessing right-ventricular function and pulmonary perfusion, Lancet, 341, 507, 10.1016/0140-6736(93)90274-K

Massoure, 2000, Upper extremity deep venous thrombosis: 40 hospitalized patients [in French], J Mal Vasc, 25, 250

Persson, 2006, Hemodynamic and morphologic evaluation of sequelae of primary upper extremity deep venous thromboses treated with anticoagulation, J Vasc Surg, 43, 1230, 10.1016/j.jvs.2006.02.045